Pfizer sets the (early) bar for coronavirus vaccines
Yesterday, partners Pfizer and BioNTech disclosed positive early results from their coronavirus vaccine candidate. And the information came not in a press release but rather a scientific paper with actual data, a welcome change for outside scientists growing tired of parsing vagaries.
As STAT’s Matthew Herper reports, the vaccine generated neutralizing antibodies in healthy volunteers, a key metric for predicting whether it will actually prevent infection. There’s no way to be sure just how big an antibody effect will be necessary to protect people from the novel coronavirus, but the data from Pfizer and BioNTech suggest a promising start that merits further study.
The paper, which hasn’t yet been peer reviewed, also establishes a benchmark for the data to come. Any day now, Moderna and its federal partners will publish detailed results from their Phase 1 vaccine trial, and Inovio Pharmaceuticals has promised to do the same in the near future. The data from Pfizer and BioNTech will serve as a useful measuring stick as more and more vaccines submit to scrutiny.
Read more.
As STAT’s Matthew Herper reports, the vaccine generated neutralizing antibodies in healthy volunteers, a key metric for predicting whether it will actually prevent infection. There’s no way to be sure just how big an antibody effect will be necessary to protect people from the novel coronavirus, but the data from Pfizer and BioNTech suggest a promising start that merits further study.
The paper, which hasn’t yet been peer reviewed, also establishes a benchmark for the data to come. Any day now, Moderna and its federal partners will publish detailed results from their Phase 1 vaccine trial, and Inovio Pharmaceuticals has promised to do the same in the near future. The data from Pfizer and BioNTech will serve as a useful measuring stick as more and more vaccines submit to scrutiny.
Read more.
No hay comentarios:
Publicar un comentario